Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery

SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies.

10x Genomics is a leader in single cell and spatial biology, with its technologies cited in more than 10,000 research publications and enabling discoveries across oncology, immunology, neuroscience and other fields.

The work brings together molecular insights generated using 10x's Xenium and Atera spatial platforms with tissue characterization from Lunit SCOPE IO. By analyzing pathology images alongside spatial molecular data, 10x aims to better understand how tissue morphology relates to the underlying biology of tumors and identify biomarkers associated with treatment response and resistance.

"10x Genomics has built powerful tools for understanding the molecular organization of tissue," said Brandon Suh, CEO of Lunit. "Lunit SCOPE IO adds the ability to analyze the full H&E landscape at scale. Together, we believe these technologies can help researchers connect deep molecular insight with the tissue patterns that pathologists recognize every day."

"Spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment," said Roman Yelensky, Vice President, Clinical Applications of 10x Genomics. "By combining that molecular depth with Lunit's AI-based analysis of the same H&E images pathologists work with every day, we can give researchers a more complete view of the tumor to accelerate the discovery of biomarkers that could inform treatment strategies and enable potential future diagnostic development."

The work will initially support oncology clinical research studies focused on antibody-drug conjugates and immunotherapy response prediction. These studies are part of 10x's broader effort to explore potential future diagnostic applications of spatial technologies in oncology.

Lunit SCOPE IO uses deep learning to analyze whole-slide H&E pathology images and characterize tissue features including tumor and stromal regions, immune-cell distribution, tertiary lymphoid structures and other features of the tumor microenvironment. Used alongside 10x's spatial technologies, these analyses provide additional tissue context that complements molecular profiling in oncology clinical research.

* Lunit SCOPE IO is for research use only. Not for use in diagnostic procedures.

About Lunit

Founded in 2013, Lunit (KRX: 328130) is a global leader on a mission to conquer cancer through AI. Our clinically validated solutions span medical imaging, breast health, and biomarker analysis, empowering earlier detection, smarter treatment decisions, and more precise outcomes across the cancer care continuum.

Lunit offers a comprehensive suite spanning risk prediction and early detection to precision oncology. Our FDA-cleared Lunit INSIGHT Breast Suite and breast health solutions support cancer screening in thousands of medical institutions worldwide, while the Lunit SCOPE platform is used in research partnership with global pharma and laboratory leaders for biomarker research, and companion diagnostic development.

Trusted by over 10,000 sites in more than 65 countries, Lunit combines deep medical expertise with continuously evolving datasets to deliver measurable impact for patients, clinicians, and researchers alike. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

SOURCE Lunit